Lantéri-Minet Michel
Department of Evaluation and Treatment of Pain, Hôpital Pasteur, CHU de Nice, Nice, France.
Eur Neurol. 2005;53 Suppl 1:3-9. doi: 10.1159/000085036. Epub 2005 May 3.
A minority of migraine sufferers are diagnosed and treated and medical consultation rates are low even among those aware of their condition. Despite guidelines recommending the use of triptans, there are high rates of usage of nonspecific treatments, mainly simple analgesics, coupled with low prevalence of triptan use. Consequently, many individuals with migraine are not receiving the kind of treatment that would meet their expectations and leave them satisfied. For patients, the most important attributes of acute migraine treatment are complete freedom from pain, rapid onset of action, no recurrence and absence of side effects. More widespread use of triptans would have the potential to improve outcomes and increase patient satisfaction, leading to a better migraine-related quality of life. In choosing among triptans, physicians need to match individual patients' needs and wants with the attributes of the particular triptans, taking into account a medication's complete profile of efficacy, consistency and tolerability, and using information from meta-analyses and modelling to ensure evidenced-based, patient-oriented decision-making.
少数偏头痛患者得到了诊断和治疗，即使在那些知晓自己病情的患者中，就医咨询率也很低。尽管有指南推荐使用曲坦类药物，但非特异性治疗的使用率很高，主要是简单的镇痛药，而曲坦类药物的使用率很低。因此，许多偏头痛患者没有得到能满足他们期望并让他们满意的治疗。对患者来说，急性偏头痛治疗最重要的特性是完全无痛、起效迅速、无复发且无副作用。更广泛地使用曲坦类药物有可能改善治疗效果并提高患者满意度，从而带来更好的偏头痛相关生活质量。在选择曲坦类药物时，医生需要将个体患者的需求与特定曲坦类药物的特性相匹配，同时考虑药物的完整疗效、一致性和耐受性概况，并利用荟萃分析和模型中的信息来确保基于证据、以患者为导向的决策。
